首页> 外文期刊>Breast Cancer Research and Treatment >Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach
【24h】

Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach

机译:使用双向验证方法推导用于乳腺癌复发预测的分子标记

获取原文
获取原文并翻译 | 示例
           

摘要

Previous studies have demonstrated the potential value of gene expression signatures in assessing the risk of post-surgical breast cancer recurrence, however, many of these predictive models have been derived using simple computational algorithms and validated internally or using one-way validation on a single dataset. We have recently developed a new feature selection algorithm that overcomes some limitations inherent to high-dimensional data analysis. In this study, we applied this algorithm to two publicly available gene expression datasets obtained from over 400 patients with breast cancer to investigate whether we could derive more accurate prognostic signatures and reveal common predictive factors across independent datasets. We compared the performance of three advanced computational algorithms using a robust two-way validation method, where one dataset was used for training and to establish a prediction model that was then blindly tested on the other dataset. The experiment was then repeated in the reverse direction. Analyses identified prognostic signatures that while comprised of only 10–13 genes, significantly outperformed previously reported signatures for breast cancer evaluation. The cross-validation approach revealed CEGP1 and PRAME as major candidates for breast cancer biomarker development. Keywords Microarray - Breast cancer prognosis - Predictive model - PRAME
机译:先前的研究已经证明了基因表达特征在评估手术后乳腺癌复发风险中的潜在价值,但是,许多预测模型是使用简单的计算算法得出的,并在内部进行了验证或对单个数据集进行了单向验证。我们最近开发了一种新的特征选择算法,该算法克服了高维数据分析固有的一些限制。在这项研究中,我们将此算法应用于从400例乳腺癌患者中获得的两个可公开获得的基因表达数据集,以研究我们是否可以得出更准确的预后特征,并揭示独立数据集中的常见预测因素。我们使用鲁棒的双向验证方法比较了三种高级计算算法的性能,其中一个数据集用于训练并建立预测模型,然后对该模型进行盲测试。然后以相反的方向重复该实验。分析确定了仅由10–13个基因组成的预后特征,但这些特征明显优于先前报道的用于乳腺癌评估的特征。交叉验证方法显示CEGP1和PRAME是乳腺癌生物标志物开发的主要候选药物。关键词芯片-乳腺癌预后-预测模型-PRAME

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号